A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy

Atherosclerosis. Supplements
Carlos AguiarRoberto Ferrari

Abstract

A meeting of European experts in cardiovascular (CV) disease and lipids was convened in Paris, France, on 10 November 2014 to discuss lipid profile, and in particular atherogenic dyslipidaemia (AD), and associated CV risk. Key points that were raised and discussed during the meeting are summarised in this paper, which also accounts for further discussion and agreement on these points by the group of experts. Elevated levels of low-density lipoprotein cholesterol (LDL-c) are commonly associated with a greater CV risk than low LDL-c levels, and are routinely managed with statins. However, even for patients controlled on statins and achieving low LDL-c levels, abnormal lipid profiles observed in some patients (i.e. elevated triglyceride levels, with/without low levels of high-density lipoprotein cholesterol [HDL-c]) have been linked to the presence of a residual CV risk. Therefore, it is recommended that both triglyceride and HDL-c levels be measured, to allow for the overall CV residual risk to be adequately managed. Favourable safety and clinical data support the combination of statins with other lipid-lowering agents, such as fenofibrate. Patients who have elevated triglyceride levels plus low levels of HDL-c are most likely to...Continue Reading

References

Jun 1, 1991·The American Journal of Cardiology·J J GenestE J Schaefer
Nov 18, 1998·The American Journal of Cardiology·C M Ballantyne
Oct 19, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Thomayant PrueksaritanontJiunn H Lin
May 27, 2003·Diabetes Care·Adam GordoisJanet Ash Tobian
May 6, 2004·International Journal of Clinical Pharmacology and Therapeutics·J WysockiZ Kalina
Feb 8, 2005·The American Journal of Cardiology·Scott M GrundyJoanne Palmisano
Jul 20, 2007·JAMA : the Journal of the American Medical Association·Børge G NordestgaardAnne Tybjaerg-Hansen
Sep 28, 2007·The New England Journal of Medicine·Philip BarterUNKNOWN Treating to New Targets Investigators
Feb 19, 2008·Journal of the American College of Cardiology·Michael MillerUNKNOWN PROVE IT-TIMI 22 Investigators
Oct 30, 2008·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Jean-Charles FruchartUNKNOWN Residual Risk Reduction Initiative (R3I)
Nov 13, 2008·JAMA : the Journal of the American Medical Association·Jacob J FreibergBørge G Nordestgaard
May 5, 2009·Diabetes·Timothy D WigginEva L Feldman
Aug 18, 2009·Fundamental & Clinical Pharmacology·Zeljko Reiner
Oct 28, 2009·Nature Reviews. Endocrinology·Paola FiorettoRobert S Rosenson
Nov 12, 2009·JAMA : the Journal of the American Medical Association·UNKNOWN Emerging Risk Factors CollaborationJohn Danesh
Jun 12, 2010·Journal of the American College of Cardiology·Ozgur BayturanSteven E Nissen
Jul 1, 2010·The New England Journal of Medicine·UNKNOWN ACCORD Study GroupLawrence J Fine
Aug 13, 2010·The New England Journal of Medicine·Christoph H SaelyHeinz Drexel
Sep 30, 2010·Diabetes Care·Solomon TesfayeUNKNOWN Toronto Diabetic Neuropathy Expert Group
Nov 6, 2010·Diabetologia·T M E DavisUNKNOWN Fenofibrate Intervention and Event Lowering in Diabetes Study investigators
Dec 4, 2010·Diabetes & Metabolism·P Valensi, S Picard
Jun 18, 2011·Diabetic Medicine : a Journal of the British Diabetic Association·L A LeiterUNKNOWN DYSIS investigators
Jun 30, 2011·European Heart Journal·UNKNOWN European Association for Cardiovascular Prevention & RehabilitationUNKNOWN ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees
Aug 16, 2011·Trends in Molecular Medicine·Laurent CamontAnatol Kontush
Sep 29, 2011·Drugs·Kate McKeage, Gillian M Keating
Aug 15, 2012·Diabetes Care·Jamie MortonUNKNOWN ADVANCE Collaborative Group
Dec 12, 2012·Current Atherosclerosis Reports·Patricia ManingatJan L Breslow
Dec 26, 2012·Journal of the American College of Cardiology·Anette VarboBørge G Nordestgaard
Oct 2, 2013·Journal of Clinical Lipidology·Peter P TothDaniel J Rader

❮ Previous
Next ❯

Citations

Nov 22, 2015·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Jesús Millán Núñez-CortésJuan Pedro-Botet Montoya
Jan 27, 2016·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·UNKNOWN Panel Europeo de Expertos. Versión Española del Grupo de trabajo sobre Dislipemia Aterogénica
Mar 8, 2016·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Juan Pedro-BotetJesús Millán Núñez-Cortés
May 14, 2016·Expert Review of Cardiovascular Therapy·T D FilippatosM Elisaf
Sep 17, 2016·Clínica e investigación en arteriosclerosis : publicación oficial de la Sociedad Española de Arteriosclerosis·Jesús MillánUNKNOWN Grupo de trabajo sobre Dislipemia Aterogénica. Sociedad Española de Arteriosclerosis
Nov 22, 2016·Expert Review of Clinical Pharmacology·T D FilippatosM S Elisaf
Mar 17, 2017·Nature Reviews. Cardiology·Željko Reiner
Jul 8, 2017·Expert Opinion on Pharmacotherapy·Niki KatsikiDimitri P Mikhailidis
Dec 1, 2017·Expert Review of Cardiovascular Therapy·Bogusław OkopieńAleksandra Bołdys
Jun 8, 2018·Critical Reviews in Clinical Laboratory Sciences·Houman TahmasebiKhosrow Adeli
Apr 16, 2020·Expert Review of Endocrinology & Metabolism·Brian TomlinsonChristopher Wai Kei Lam
May 8, 2020·Lipids in Health and Disease·Irina CrismaruCamelia Cristina Diaconu
Nov 8, 2018·Korean Circulation Journal·Željko Reiner
May 24, 2017·European Heart Journal Supplements : Journal of the European Society of Cardiology·Roberto FerrariAlberico L Catapano
May 10, 2017·Infection·Sebastian Filippas-NtekouanMoses Elisaf
Dec 2, 2017·Journal of Veterinary Internal Medicine·E C SeageR S Hess
Jul 29, 2017·European Heart Journal Supplements : Journal of the European Society of Cardiology·Michele Massimo GuliziaAttilio Maseri
Apr 8, 2021·Expert Opinion on Pharmacotherapy·Brian TomlinsonChristopher Wai Kei Lam
Apr 11, 2021·Journal of Cardiovascular Pharmacology and Therapeutics·Semira Abdi BeshirAmira S A Said
Jul 22, 2021·Critical Reviews in Food Science and Nutrition·Yuling LiJiaqi Shuai
Sep 1, 2021·Journal of Clinical Lipidology·Marie MaraninchiRené Valéro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.